{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-091222","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.709949+00:00","generated_at":"2026-06-23T23:41:22.718845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eloxx Q2 net loss $10.6M; cash $30M; CF topline data expected Q3 2022","bullets":["Q2 2022 net loss $10.6M ($0.12/sh) vs $36.1M ($0.54/sh) in Q2 2021; prior year included $22.7M Zikani acquisition expense.","Cash and equivalents $30.0M as of June 30, 2022; sufficient to fund operations into Q4 2023; in compliance with debt covenants.","CF Phase 2 expansion arms top-line results expected by end of Q3 2022; inhaled delivery IND on track for Q4 2022.","Alport syndrome proof-of-concept trial to start H2 2022 in up to 8 patients; topline results expected H1 2023.","ZKN-013 repeat study confirms potential in FAP model; IND for FAP expected H2 2023; RDEB IND on track for Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-091222","json":"https://secwatch.observer/filing/0001104659-22-091222.json","markdown":"https://secwatch.observer/filing/0001104659-22-091222.md","text":"https://secwatch.observer/filing/0001104659-22-091222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922091222/0001104659-22-091222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922091222/tm2223461d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:41:22.718845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}